• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » FDA Suggests Statistical Strategies for Mitigating Data Loss During the Pandemic

FDA Suggests Statistical Strategies for Mitigating Data Loss During the Pandemic

June 22, 2020

Sponsors of trials impacted by the COVID-19 pandemic have several statistical analysis options for mitigating the effect of missing data, according to a final guidance from the FDA that outlines strategies the agency considers acceptable.

The guidance notes that multiple strategies may be needed to adequately address the COVID-19 impact. Strategies include collecting information on discontinuation of treatment, withdrawal of a patient from the trial, use of alternative or rescue treatments, and missed or alternative endpoint assessments to incorporate into the statistical analysis plan.

Sponsors that consider stopping a trial early and conducting final analysis may perform a blinded power assessment to determine what effect the smaller data pool might have on the validity of statistical conclusions. The guidance cautions that any trial that is stopped earlier than planned must avoid changing the planned analysis in a way that would introduce bias.

It also may be reasonable to exclude patients from the data pool if they were not able to receive the full benefit of the treatment being studied.

Trials also may plan to gather additional data by enrolling additional participants and extending the trial period beyond the end of the pandemic or by extending the patient follow-up period after treatment ends.

Modifications of trial endpoints and statistical analysis plans should be discussed with the FDA, the guidance says.

Read the guidance here: https://bit.ly/3dor6uB.

Upcoming Events

  • 24May

    Powering an Effective Oversight Strategy with Clinical and Operational Insights

  • 25May

    2022 WCG Avoca Quality & Innovation Summit: Own the Future

  • 28Jun

    Effective Root Cause Analysis and CAPA Investigations for the Life Sciences

  • 16Oct

    WCG MAGI's Clinical Research Hybrid Conference - 2022 West

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • Protocol-360x240.png

    Avoid Deviations by Making Protocol Review a Team Effort

  • SelectionProcess-360x240.png

    Give Us a Voice: Sites Clamor for a Say on Vendor Selection

  • Convince-360x240.png

    Use Data and Details to Convince Site Leadership to Add Staff

  • AsktheExpertsBadge-360x240.png

    Ask the Experts: Listing Trial Staff and Others on the Statement of Investigator

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell My Personal Information

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2022. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing